Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival

In his first appearance since Bristol-Myers Squibb completed its takeover last week of Celgene (CELG), Giovanni Caforio offered a predictably upbeat prognosis for the newly combined company but sidestepped questions about rival Merck’s ongoing dominance of immunotherapy, a key area that has been tinged with disappointment for the poker-faced executive.